Karyopharm Therapeutics Inc. Operating Cash Flow
Karyopharm Therapeutics Inc. (KPTI) reported Operating Cash Flow of -$47.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$24.93M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$22.73M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.83M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$5.86M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$75.37M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$127.49M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$92.72M.
- Karyopharm Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$149.55M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$24.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$47.66M 10-Q · filed 2026-08-13 | -$59.49M derived: sum of 3 quarters · filed 2026-08-13 | -$65.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$22.73M 10-Q · filed 2026-05-14 | -$34.56M derived: sum of 2 quarters · filed 2026-05-14 | -$40.42M derived: sum of 3 quarters · filed 2026-05-14 | -$59.11M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$17.69M derived: sum of 2 quarters · filed 2026-02-13 | -$36.38M derived: sum of 3 quarters · filed 2026-08-13 | -$75.37M 10-K · filed 2026-02-13 |
| 2025-09-30 | -$5.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$24.56M derived: sum of 2 quarters · filed 2026-08-13 | -$63.54M 10-Q · filed 2025-11-03 | -$89.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$18.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$57.68M 10-Q · filed 2026-08-13 | -$83.49M derived: sum of 3 quarters · filed 2026-08-13 | -$102.94M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$38.98M 10-Q · filed 2026-05-14 | -$64.79M derived: sum of 2 quarters · filed 2026-05-14 | -$84.25M derived: sum of 3 quarters · filed 2026-05-14 | -$122.75M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$25.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$45.26M derived: sum of 2 quarters · filed 2026-02-13 | -$83.76M derived: sum of 3 quarters · filed 2026-02-13 | -$127.49M 10-K · filed 2026-02-13 |
| 2024-09-30 | -$19.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$57.95M derived: sum of 2 quarters · filed 2025-11-03 | -$101.68M 10-Q · filed 2025-11-03 | -$120.26M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-06-30 | -$38.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$82.22M 10-Q · filed 2025-08-11 | -$100.81M derived: sum of 3 quarters · filed 2026-02-13 | -$130.34M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-03-31 | -$43.73M 10-Q · filed 2025-05-12 | -$62.31M derived: sum of 2 quarters · filed 2026-02-13 | -$91.84M derived: sum of 3 quarters · filed 2026-02-13 | -$117.54M derived: sum of 4 quarters · filed 2026-02-13 |
| 2023-12-31 | -$18.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$48.12M derived: sum of 2 quarters · filed 2026-02-13 | -$73.81M derived: sum of 3 quarters · filed 2026-02-13 | -$92.72M 10-K · filed 2026-02-13 |
| 2023-09-30 | -$29.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$55.23M derived: sum of 2 quarters · filed 2024-11-05 | -$74.14M 10-Q · filed 2024-11-05 | -$100.98M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | -$25.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$44.61M 10-Q · filed 2024-08-06 | -$71.45M derived: sum of 3 quarters · filed 2025-02-19 | -$99.82M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$18.91M 10-Q · filed 2024-05-08 | -$45.75M derived: sum of 2 quarters · filed 2025-02-19 | -$74.12M derived: sum of 3 quarters · filed 2025-02-19 | -$109.27M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | -$26.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$55.21M derived: sum of 2 quarters · filed 2025-02-19 | -$90.36M derived: sum of 3 quarters · filed 2025-02-19 | -$149.55M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$28.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$63.51M derived: sum of 2 quarters · filed 2023-11-02 | -$122.71M 10-Q · filed 2023-11-02 | -$97.24M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$35.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$94.34M 10-Q · filed 2023-08-02 | -$68.87M derived: sum of 3 quarters · filed 2024-02-29 | -$92.82M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$59.20M 10-Q · filed 2023-05-04 | -$33.72M derived: sum of 2 quarters · filed 2024-02-29 | -$57.68M derived: sum of 3 quarters · filed 2024-02-29 | -$113.42M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $25.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.52M derived: sum of 2 quarters · filed 2024-02-29 | -$54.23M derived: sum of 3 quarters · filed 2024-02-29 | -$107.12M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$23.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$79.70M derived: sum of 2 quarters · filed 2022-11-03 | -$132.59M 10-Q · filed 2022-11-03 | -$163.22M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | -$55.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$108.64M 10-Q · filed 2022-08-04 | -$139.27M derived: sum of 3 quarters · filed 2023-02-17 | -$183.58M derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | -$52.89M 10-Q · filed 2022-05-05 | -$83.52M derived: sum of 2 quarters · filed 2023-02-17 | -$127.83M derived: sum of 3 quarters · filed 2023-02-17 | -$168.11M derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | -$30.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | -$74.95M derived: sum of 2 quarters · filed 2023-02-17 | -$115.22M derived: sum of 3 quarters · filed 2023-02-17 | -$160.23M 10-K · filed 2023-02-17 |
| 2020-09-30 | -$44.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$84.59M derived: sum of 2 quarters · filed 2021-11-03 | -$129.60M 10-Q · filed 2021-11-03 | -$169.09M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$40.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$85.29M 10-Q · filed 2021-08-05 | -$124.78M derived: sum of 3 quarters · filed 2022-03-01 | -$161.28M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$45.01M 10-Q · filed 2021-05-04 | -$84.50M derived: sum of 2 quarters · filed 2022-03-01 | -$121.01M derived: sum of 3 quarters · filed 2022-03-01 | -$169.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$39.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$76.00M derived: sum of 2 quarters · filed 2022-03-01 | -$124.20M derived: sum of 3 quarters · filed 2022-03-01 | -$190.82M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$36.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | -$84.71M derived: sum of 2 quarters · filed 2020-11-02 | -$151.33M 10-Q · filed 2020-11-02 | -$199.50M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$48.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$114.83M 10-Q · filed 2020-08-04 | -$163.00M derived: sum of 3 quarters · filed 2021-02-24 | -$201.66M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$66.62M 10-Q · filed 2020-05-05 | -$114.80M derived: sum of 2 quarters · filed 2021-02-24 | -$153.46M derived: sum of 3 quarters · filed 2021-02-24 | -$191.09M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | -$48.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$86.84M derived: sum of 2 quarters · filed 2021-02-24 | -$124.47M derived: sum of 3 quarters · filed 2021-02-24 | -$159.12M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$38.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | -$76.29M derived: sum of 2 quarters · filed 2019-11-04 | -$110.94M 10-Q · filed 2019-11-04 | -$116.48M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | -$37.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$72.28M 10-Q · filed 2019-08-07 | -$77.82M derived: sum of 3 quarters · filed 2020-02-26 | -$99.57M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | -$34.65M 10-Q · filed 2019-05-09 | -$40.19M derived: sum of 2 quarters · filed 2020-02-26 | -$61.94M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2017-12-31 | -$5.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$27.29M derived: sum of 2 quarters · filed 2020-02-26 | -$73.72M 10-K · filed 2020-02-26 | |
| 2017-09-30 | -$21.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$68.18M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$46.43M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | -$84.39M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |